Gyermekkori daganatok: vizsgálatok itt: Lengyelország
49 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Bialystok, Cracow, Gdansk, Gliwice, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 15 év and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - 2. fázisTaking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Gdansk, Wroclaw
- Életkor
- 1 év to 18 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Katowice, Krakow, Warsaw, Wroclaw
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - 3. fázisTaking peopleA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Where
- Gda?sk, Koszalin, Warsaw
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00 - 1/2. fázisTaking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Wroclaw
- Életkor
- 6 hónap to 30 év
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - 1/2. fázisTaking peopleA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Wroclaw
- Életkor
- Up to 17 év
- People
- 37 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 - 2/3. fázisTaking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Bytom, Gdansk, Gliwice, Lodz, Lublin, Warsaw
- People
- 1541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - 1. fázisNot yet taking people in LengyelországPhase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
- Where
- Warsaw
- Életkor
- Up to 17 év
- People
- 48
- Run by
- Instytut Pomnik Centrum Zdrowia Dziecka
See details and how to join2025-524031-39-00 - No phaseTaking peopleMaster Framework For Relapse or Refractory Acute Myeloid Leukemia
- Where
- Gdansk
- Életkor
- 6 év and over
- People
- 4000 worldwide
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024 - 3. fázisTaking peopleInternational Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- Where
- Wroclaw
- Életkor
- 1 év to 64 év
- People
- 750 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00 - 3. fázisTaking peopleFight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
- Where
- Warsaw
- Életkor
- 4 év and over
- People
- 530 worldwide
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864 - 2/3. fázisTaking peopleEfficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
- Where
- Lodz, Warsaw
- Életkor
- 4 hét to 16 hét
- People
- 60
- Run by
- Katarzyna Kotulska
See details and how to joinNCT04987463 · EU 2024-513068-25-00 - 3. fázisTaking peoplePlacebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
- Where
- Lodz, Warsaw
- Életkor
- 3 hónap to 50 év
- People
- 200
- Run by
- Katarzyna Kotulska
See details and how to joinNCT05534672 · EU 2024-515937-13-00 - 3. fázisTaking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Bydgoszcz, Lublin, Olsztyn, Opole, Walbrzych, Wroclaw
- Életkor
- 12 év and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - 2/3. fázisTaking peopleFramework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
- Where
- Poznan
- Életkor
- 3 hónap to 25 év
- People
- 1000 worldwide
- Run by
- Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00 - 3. fázisTaking peopleInternational Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
- Where
- Warsaw
- Életkor
- Up to 64 év
- People
- 1351 worldwide
- Run by
- GPOH gGmbH
See details and how to join2022-501180-40-00 - 3. fázisTaking peopleInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Where
- Bialystok, Bydgoszcz, Chorzów, Cracow, Gdansk, Katowice, Kielce, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw, Zabrze
- Életkor
- 1 nap to 1 év
- People
- 160 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00 - 1. fázisNot yet taking people in LengyelországStudy of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
- Where
- Warsaw
- Életkor
- 3 év to 18 év
- People
- 48
- Run by
- Bożenna Dembowska Bagińska
See details and how to joinNCT07865130 - 2. fázisTaking peopleTo Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
- Where
- Warsaw, Wroclaw
- Életkor
- 2 év to 21 év
- People
- 24
- Run by
- Anna Raciborska
See details and how to joinNCT05968768 - 2. fázisTaking peopleEvaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
- Where
- Warsaw
- Életkor
- 5 hónap to 30 év
- People
- 40
- Run by
- Anna Raciborska
See details and how to joinNCT07787429 - 2/3. fázisTaking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Gdansk, Gliwice, Konin, Siedlce, Warsaw
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - 2. fázisTaking peopleStudy With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
- Where
- Bialystok, Bydgoszcz, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Warsaw
- Életkor
- 0 hónap to 18 év
- People
- 95 worldwide
- Run by
- Helsinn Healthcare SA
See details and how to joinNCT06904235 - 2. fázisTaking peopleA Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- Where
- Bydgoszcz, Wroclaw
- Életkor
- 1 év to 17 év
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00 - 3. fázisTaking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Cracow, Gdansk, Gliwice, Poznan, Warsaw, Warszawa
- Életkor
- 12 év to 100 év
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - 2/3. fázisTaking peopleAllogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
- Where
- Bydgoszcz, Krakow, Lublin, Poznan, Wroclaw
- Életkor
- 1 hónap to 18 év
- People
- 1800 worldwide
- Run by
- St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00